% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wagemann:285734,
author = {Wagemann, Olivia and Götz, Charlotte and Wlasich,
Elisabeth and Sandkühler, Katja and Prix, Catharina and
Stockbauer, Anna and Marth, Lena and Jäck, Alexander and
Halbgebauer, Steffen and Tumani, Hayrettin and Höglinger,
Günter U and Levin, Johannes and Nübling, Georg},
title = {{C}ombining blood biomarkers and the {G}erman version of
the {D}ementia {S}creening {Q}uestionnaire for {I}ndividuals
with {I}ntellectual {D}isabilities ({DSQIID}-{G}) for
diagnosing cognitive decline in {D}own syndrome.},
journal = {Alzheimer's and dementia},
volume = {22},
number = {3},
issn = {1552-5260},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {DZNE-2026-00291},
pages = {e71296},
year = {2026},
abstract = {Individuals with Down syndrome (DS) are at risk for
Alzheimer's disease (AD). However, diagnosis remains
challenging due to variability of intellectual ability and
symptom presentation. To investigate whether serum AD
biomarkers enhance accuracy of the German version of the
Dementia Screening Questionnaire for Individuals with
Intellectual Disabilities (DSQIID-G), we combined test
scores with neurofilament light chain (NfL) and glial
fibrillary acidic protein (GFAP) levels.Seventy-eight DS
individuals $(49\%$ female) completed the DSQIID-G; previous
cohort data were added for a pooled sample (n = 164, $47\%$
female). Serum NfL and GFAP were assessed using the
automated microfluid Ella system.Combining the DSQIID-G with
NfL or GFAP resulted in improved accuracy in every
diagnostic subgroup. The Youden index in the pooled samples
yielded a cut-off score at 6.5.The DSQIID-G is a robust
screening tool and its combination with AD blood biomarkers
aids earlier identification of individuals requiring further
diagnostics for DS-associated AD.},
keywords = {Humans / Down Syndrome: complications / Down Syndrome:
blood / Female / Male / Biomarkers: blood / Neurofilament
Proteins: blood / Middle Aged / Cognitive Dysfunction:
diagnosis / Cognitive Dysfunction: blood / Surveys and
Questionnaires / Glial Fibrillary Acidic Protein: blood /
Germany / Intellectual Disability: blood / Intellectual
Disability: complications / Aged / Dementia: diagnosis /
Dementia: blood / Adult / Alzheimer's disease (Other) /
Dementia Screening Questionnaire for Individuals with
Intellectual Disabilities (Other) / Down syndrome (Other) /
blood biomarker (Other) / glial fibrillary acidic protein
(Other) / neurofilament light chain (Other) / screening
(Other) / Biomarkers (NLM Chemicals) / Neurofilament
Proteins (NLM Chemicals) / neurofilament protein L (NLM
Chemicals) / Glial Fibrillary Acidic Protein (NLM
Chemicals)},
cin = {Clinical Research (Munich)},
ddc = {610},
cid = {I:(DE-2719)1111015},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41859776},
doi = {10.1002/alz.71296},
url = {https://pub.dzne.de/record/285734},
}